Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Facebook
Linkedin
Twitter
Home
R&D
FINANCE
MANUFACTURING
APPROVALS
SUPPLY CHAIN
LAUNCHES
EVENTS
EVENTS NEWS
EVENT LISTINGS
APPOINTMENTS
Search
Home
Featured
Page 94
Featured
Featured posts
Random
Latest
Featured posts
Most popular
7 days popular
By review score
Random
FDA approves Geron’s RYTELO for the treatment of adults with lower-risk MDS with transfusion-dependent anemia
14th June 2024
Quell Therapeutics and AstraZeneca to develop engineered Treg cell therapies for autoimmune diseases
Gilead and Dragonfly to develop natural killer cell engagers in oncology and inflammation
UCB to acquire biopharmaceutical company developing therapies for rare diseases
UK makes £39m cash injection into AMR research
Iveric Bio receives U.S. FDA approval for IZERVAY for geographic atrophy
7th August 2023
Essential Pharma acquires Reminyl oral capsules
18th April 2024
AbbVie and Gedeon Richter to develop novel treatments for neuropsychiatric diseases
14th March 2022
FDA grants accelerated approval to BeiGene’s BRUKINSA to treat relapsed or...
11th March 2024
Tonix Pharmaceuticals and Kansas State University to develop new mRNA vaccines...
6th January 2022
Enhertu approved in the US as the first HER2-directed therapy for...
16th August 2022
RYSTIGGO, for generalized myasthenia gravis, receives EU approval for two new...
3rd February 2025
FivepHusion forms strategic collaboration with Treehill Partners and Syneos Health to...
1st June 2023
Lilly and Regor enter into strategic collaboration to develop novel therapies...
13th December 2021
Be Bio closes $130m financing to advance engineered B cell medicines
19th April 2022
1
...
93
94
95
...
146
Page 94 of 146
News
AbbVie and Xilio Therapeutics to develop novel tumor-activated immunotherapies
14th February 2025
AbbVie and Xilio Therapeutics, a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, have announced a collaboration and...
Duchenne muscular dystrophy market to reach $5.2 billion in 7MM by 2033, forecasts GlobalData
14th February 2025
The Duchenne muscular dystrophy (DMD) market across the seven major markets (7MM*) is set to grow from $2.3 billion in 2023 to $5.2 billion...
Royalty Pharma to provide $250m R&D funding in Biogen lupus collaboration
13th February 2025
Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a...